American Society of Hirudotherapy

Extracorporeal membrane oxygenation (ECMO) in pediatric congenital heart disease: a comprehensive review

Review published in The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology (2025)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewGenomics & ProteomicsFaheem MSB et al. · The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 2025

Abstract

BACKGROUND: Extracorporeal membrane oxygenation (ECMO), which provides life-saving assistance in severe cardiac and pulmonary failure cases, has emerged as an important technique in managing children with congenital heart disease (CHD). MAIN BODY: In this review, we discuss the evolution of ECMO over the years, its clinical uses, and the results in pediatric CHD. ECMO has been utilized as a bridge to recovery, in stabilizing an individual after surgery, and as a bridge to heart transplantation. Cannulation procedures that are adjusted according to the anatomy of an individual have improved outcomes, although bleeding and neurologic concerns remain a matter of concern. In addition, long-term neurodevelopmental disorders and renal failure are also among the alarming outcomes. The use of newer anticoagulant drugs like bivalirudin, which lowers the risk of bleeding, and genomic testing for personalized treatment are examples of recent developments. Furthermore, neuroprotective techniques such as erythropoietin and dexmedetomidine can also enhance the neurocognitive outcomes. Finally, improvements in monitoring systems and pump technology contribute to increased ECMO efficacy and safety. CONCLUSION: Despite these developments, ECMO's expense and restricted accessibility remain major obstacles, especially in areas with low resources. In this review, the advancements in ECMO technology and care are highlighted, and it also emphasizes future research to address the current challenges.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Summary

This review describes ECMO as a bridge to recovery, surgical stabilisation, or transplantation in pediatric congenital heart disease, highlighting newer anticoagulants like bivalirudin, neuroprotective strategies, and advances in cannulation, monitoring, and pump technology alongside bleeding and neurodevelopmental concerns.

Why This Matters for Hirudotherapy

This review discusses extracorporeal membrane oxygenation (ECMO) in pediatric congenital heart disease, covering its evolution, clinical uses (bridge to recovery, post-surgical stabilization, bridge to transplantation), complications such as bleeding and neurologic and renal concerns, and recent developments including newer anticoagulants like bivalirudin, noted for lowering bleeding risk, neuroprotective strategies, and monitoring and pump improvements. The abstract mentions bivalirudin only as one of several advances and contains no mention of hirudin, leeches, or leech-derived therapeutics. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Faheem MSB, Qurat Ul Ain H, Haroon-Ul-Rasheed M, Aftab R. Extracorporeal membrane oxygenation (ECMO) in pediatric congenital heart disease: a comprehensive review. Egypt Heart J. 2025;77(1):34. doi:10.1186/s43044-025-00630-6. PMID: 40126700

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.